Trials / Completed
CompletedNCT01200784
Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
Dose Finding Study of Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 252 (actual)
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nicotinamide | dosage |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-06-01
- Completion
- 2011-07-01
- First posted
- 2010-09-14
- Last updated
- 2012-01-18
Locations
36 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01200784. Inclusion in this directory is not an endorsement.